Ganymed Robotics, a developer of computer vision software and robotic technologies dedicated to orthopedic surgery, announced in early July that it had raised €21M in a Series B financing round. The round was led by Cathay Health, with the participation of Crédit Mutuel Innovation, Kurma Partners, BNP Paribas Développement and world-renowned surgeons.

Over the past thirty years, robotic systems have continued to progress, improving the precision and reproducibility of surgical procedures. The interventions are less invasive, less traumatic, preserving the musculature around the joints. Regardless of the brand, material and model of joint prosthesis chosen by a surgeon, the quality of the fitting is essential. Today, 95% of orthopedic surgeries are performed without technological or robotic assistance, with a very high patient dissatisfaction rate of over 20%.

The Ganymed Robotics platform

Founded in 2018, based in Paris, headed by Sophie Cahen, Ganymed Robotics has 25 employees. Its mission is to improve patient outcomes, the surgeon’s experience and the overall efficiency of joint replacement procedures.To this end, the start-up has developed, in close collaboration with world-renowned physicians and consultants, a proprietary technology platform based on computer vision and mechatronics. This platform allows surgeons to provide patient-specific care without the hassle and invasiveness of cutting guides, optical tracking and intramedullary rods.

Ganymed Robotics has received a €2.5M grant and a €10M investment from the European Council for the development and industrialization phase of its first application, a surgeon co-manipulated arm dedicated to knee replacement, which has been validated on 100 patients.

A €21 million fundraising round

This Series B round of financing will allow the company to :

• Accelerate the expansion of Ganymed in France and the United States;
• Finalize the industrialization of its first application;
• Accelerate regulatory and marketing developments in several geographies;
• Diversify its application portfolio based on its proprietary technology platform.

Sophie Cahen, co-founder and President of Ganymed Robotics, states:

“The support of such a prestigious group of investors in innovation and health represents a strong validation of the work accomplished by the entire team. This new stage of development, which brings us to market, will be critical in our journey as a future champion of interventional medical technologies. With our robotic computer vision platform, we aim to provide surgeons and healthcare centers of all sizes with an easy-to-use, cost-effective device that will dramatically improve surgical practice and patient satisfaction in orthopedics.”

Translated from Ganymed Robotics annonce une levée de fonds de 21 millions d’euros